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Summary We have examined two new oestrogen receptor (ER) assays - an enzyme immunoassay (EIA) and
an immunocytochemical assay (ICA) in a large series of primary breast tumours to compare their potential as
predictors of (1) response to endocrine therapy and (2) survival in patients developing advanced breast cancer.
Response to endocrine therapy was categorised at 6 months (UICC criteria). ERICA appears the better
predictor of response to endocrine therapy than ER-EIA. Combining ICA and EIA results did not improve
the prediction of response.
With both assays patients with ER positive tumours survived longer from the time of diagnosis of advanced
disease than those with ER negative tumours. The predictive power of these assay for progression of disease
appears slightly better for the ER-ICA.
One measure of the clinical value of a hormone receptor
assay in breast cancer is the accuracy with which it predicts
response to systemic endocrine therapy. Response to therapy
has been reported to correlate significantly with both oestro-
gen receptor (ER) status (Blamey et al., 1980; Jensen, 1981;
Stewart et al., 1982; Williams et al., 1986) and progesterone
receptor (PgR) status (Stewart et al., 1982; McGuire, 1978;
Johnson et al., 1983). Survival from commencing endocrine
therapy has also been reported to correlate significantly with
ER status (Hahnel et al., 1979; Stewart et al., 1981; Kinne et
al., 1981; Paterson et al., 1982; Howat et al., 1985; Williams
et al., 1987) and PgR status (Howat et al., 1985; Howell et
al., 1984) of the primary tumour.
In recent years two new ER assays have become available
from Abbott Laboratories an enzyme immunoassay (ER-
EIA) and immunocytochemical assay (ER-ICA): both based
on a monoclonal antibody (H222) that was raised to human
ER. Although a previous study from our group has reported
a statistically significant correlation between the ER-EIA and
the ER-ICA in primary tumours (Walker et al., 1988), to the
authors knowledge no direct evaluation of the relative ability
of these new assays to predict response to systemic endocrine
therapy and survival from commencing treatment in patients
with advanced breast cancer has been undertaken. This has
been addressed in the current paper.
Patients and methods
This study reports 192 patients with advanced breast cancer
treated by primary endocrine therapy all of whom were
assessable for response by International Union Against
Cancer criteria (UICC) (Hayward et al., 1977). Eighty-one
patients received hormone therapy either for local disease
(i.e. a locally advanced primary cancer or for recurrent local
disease) while the remaining 111 patients had metastatic
disease. The major sites of metastatic disease were bone only
(n = 41), lung/soft tissue only (n = 30), bone and lung/soft
tissue (n = 12) and visceral (n = 28).
All patients at initial presentation had primary tumour
tissue available for oestrogen receptor measurement. Speci-
mens consisted either of tumour biopsies removed in the
out-patient clinic or surgical excision specimens. All speci-
mens were immediately frozen in liquid nitrogens and main-
tained at a minimum of - 70°C until their assay in the Breast
Cancer Unit of the Tenovus Institute for Cancer Research,
Cardiff. Two types of oestrogen receptor assay were carried
out using ER-EIA and ER-ICA kits obtained from Abbott
Laboratories. Each assay has been described in detail
(Nicholson et al., 1986; Walker et al., 1988) and will only be
outlined here. The ER-EIA involved incubating cytosol frac-
tions of the breast tumours with antibody (rat anti-human
ER, D547) coated polystyrene beads. This immobilises the
receptor prior to its incubation with a second antibody (rat
anti-human ER H222) that has been conjugated with horse-
radish peroxidase. Following incubation and subsequent
washing steps the concentration of horseradish peroxidase
was determined using diaminobenzidine and H202 and is
directly proportional to the concentration of ER. This pro-
vides a quantitative assessment of the receptor protein.
The ER-ICA procedure also utilises H222, but this time in
a peroxidase - antiperoxidase (PAP) assay system. Briefly,
H222 is incubated with a 5 tLm frozen section of the breast
tumours' and after washing, this was followed by a bridging
antibody (goat anti-rat IgG) and finally a rat PAP complex.
Peroxidase activity is detected by the incubation of the anti-
body complex with diaminobenzidine and H202, with the
insoluble reaction product marking the presence of the ER in
the section.
In 98 patients oestrogen receptor status was measured by
both the enzyme immunoassay (EIA) and immunocyto-
chemical assay (ICA). In 80 patients oestrogen receptor
status was measured using EIA alone and in 14 patients by
ER-ICA alone. Therefore out of a total of 192 patients 178
had results for ER-EIA status and 112 patients had results
for ER-ICA status.
In this study we have used a cut-off level of < 15 fmol
mg-' cytosol protein for the ER-EIA assay. Tumours were
regarded as ER negative by the ER-ICA assay if <5% of
tumour cells stained positive.
Assessment
Patients have been assessed for complete or partial response
(CR or PR), static disease (SD) and progression (PD)
according to UICC criteria (Hayward et al., 1977). As
recommended by the British Breast Group (British Breast
Group, 1974) it is our policy to assess patients for response
and static disease 6 months after commencing hormone
therapy.
All patients have been followed up for time to disease
progression and for survival from commencement of primary
hormone therapy.
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Statistical analyses
Data were analysed using the statistical package SPSSX-21
(SPSS, 1986). Chi squared analysis with Yates correction
where appropriate were used to compare frequencies of inte-
gers between two variables. Comparison of ER concentra-
tions between groups was made using the Kruskal-Wallis test
for non-parametric data. Survival between different groups
was analysed using a modification of Gehan's generalised
Wilcoxon test (Lee & Desu, 1972). In accordance with con-
vention in all analysis P<0.05 was taken as significant.
Results
Twenty-one patients showed a complete response and 21 a
partial response at 6 months and 50 patients had static
disease at 6 months. One hundred patients showed progres-
sion of disease within 6 months of commencing endocrine
therapy.
ER expression was analysed to assess whether premeno-
pausal and postmenopausal patients could be combined into
a single group. Postmenopausal patients had significantly
more ER positive tumours by ER-ICA (i.e. >5% tumour
cells positive) than premenopausal patients (P<0.03; x2
test). The concentration of ER in the tumour as determined
by ER-EIA assay (fmoles mg-' cytosol protein) was also
significantly higher in postmenopausal patients (P<0.005;
Kruskal-Wallis test).
ER concentrations of the primary tumour was also cor-
related with the age of patients, based around the age limits
of the United Kingdom Breast Cancer Screening Programme
(i.e. 50-65 years). Patients were grouped as <50 years (i.e.
premenopausal) or into one of two postmenopausal groups,
50-65 years or >65 years. Tumours were divided on the
basis of the ER concentration by ER-EIA assay into < 10,
11-100, 101-300 or >300fmolesmg-' cytosol protein. ER
expression correlated significantly with age (Table I) (P=
0.008; x2 test). Even between the two postmenopausal groups
there were more patients with high ER concentration in the
group of older patients (i.e. >65 years) (Table I).
We further examined the relationship between ER concen-
tration and menopausal status to assess whether the same
cut-off level was appropriate in premenopausal and post-
menopausal patients in assessing response. A cut-off of
15 fmoles mg-' cytosol protein was selected and analysed to
assess whether premenopausal and postmenopausal patients
below or above this level had significantly different response
rates. There was no difference using 15 fmolesmg-' cytosol
protein as the cut-off. We repeated the analysis using 50 and
100 fmolesmg-' cytosol protein as cut-off levels and again
found no difference in response rates between premenopausal
and postmenopausal patients.
While the results above indicate that as a group post-
menopausal patients have significantly higher levels of ER
expression in their tumours these results also show that
tumours with equal concentrations of ER show similar res-
ponse rates irrespective of menopausal status of patients.
Since as a group postmenopausal patients have higher con-
centrations of ER the response rate in a group of post-
menopausal patients would be expected to exceed that found
in a group of premenopausal patients. However this differ-
ence in response rate by menopausal status failed to reach
statistical significance (P = 0.09; x2 test).
In view of the above results showing that the same cut-off
levels for ER expression can be used in all patients, we
combinated premenopausal and postmenopausal patients
into a single group. ER concentration by ER-EIA assay was
correlated with the site of initial disease (Figure 1). There
was a significant difference in ER concentration between
patients with local disease and patients with metastatic
disease (P<0.02; Kruskal Wallis test). Further analyses
showed that the only significant difference was between
patients with local disease and patients with lung metastases
(P<0.002; Kruskal Wallis test). This difference in ER con-
Table I Patient age vs ER expression (ER-EIA assay)
ER concentration Age (years)
(fmolesmg-' protein) <50 50-65 >65
<10 19 21 17
11-100 26 21 16
101-300 7 19 9
>300 1 7 12
x2 = 17.3, 6 d.f.; P = 0.008.
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Figure 1 ER by site of initial disease.
centration would explain the significant difference in response
rates between different sites of initial disease: patients with
local disease had a significantly higher response rate than
patients with metastatic disease (x2= 53.9; 1 d.f.: P<
0.0001).
Response to treatment and survival was compared separ-
ately with hormone receptor status measured by ER-EIA and
ER-ICA.
ER-EIA status
One hundred and seventy-eight patients had ER-EIA recep-
tor status measured. At presentation 49 were premenopausal
and 129 postmenopausal. The main site of disease on com-
mencing hormone therapy was local disease (n = 72), bone
metastasis only (n = 38), lung/soft tissue metastasis (n = 29),
bone and lung/soft tissue metastasis (n = 12) and visceral
metastasis (n = 27). One hundred and thirty-two patients
were treated with tamoxifen, 20 mg b.d., 39 patients with
goserelin (Zoladex, ICI Pharmaceuticals, UK), 3.6 mg by
monthly subcutaneous injection alone or in combination with
tamoxifen and seven patients with megestrol acetate (Megace,
Bristol Myers, UK), 160 mg b.d. ER-EIA receptor status
correlated significantly with UICC assessed response at 6
months as shown in Table TT. ER-EIA status also correlated
significantly with time to progression of disease (Wilcoxon
statistic = 27.7, 1 d.f.; P<0.0001), (Figure 2) and with sur-
vival (Wilcoxon statistic = 26.5, 1 d.f. P<0.0001), (Figure 3):
patients with ER-EIA positive tumours have a much more
favourable outlook.
ER-ICA status
One hundred and twelve patients had ER-ICA receptor
status measured, 27 premenopausal and 85 postmenopausal.
The main site of disease on commencing hormone treatment
was local disease (n = 60), bone metastasis only (n = 18), soft
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Table II UICC assessed response to primary hormone therapy by ER
status of the primary tumour
CR PR Static Prog.
ER-EIA
- 1 4 10 50 X2=23.6, 3d.f.;
+ 17 11 39 46 P<0.0001
ER-ICA
- 0 0 6 35 x2= 38.4, 3d.f.;
+ 14 15 23 19 P<0.0001
CR = complete response; PR + partial response; Static = static
disease; Prog. = progressive disease.
Table III UICC assessed response to primary hormone therapy by
ER-ElA/ER-ICA of the primary tumour combined
CR PR Static Prog.
ER-ICA/ER-EIA
++ 10 9 22 17
+ - 1 0 0 1
-+ 0 0 3 9
-- 0 0 3 23
x2= 33.9, 9 d.f.; P<0.0001.
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EIA positive 112 79 45 25 14 9 3
ICA positive 70 56 34 20 10 3 1
EIA negative 65 21 9 5 3 1 1 1 1
ICA negative 41 13 2 1
Figure 2 Probability of progression by ER status. -El-, ER-
EIA positive; -U-, ERICA positive; -*-, ER-EIA negative;
-O-, ERICA negative.
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EIA positive 113 99 86 57 39 30 13 5 5
ICA positive 71 66 58 44 30 20 8 4 3
EIA negative 65 42 24 14 8 3 3 3 2
ICA negative 41 31 18 8 4
Figure 3 Probability of survival by ER status. -0 , ER-EIA
positive; -U-, ERICA positive; *-, ER-EIA negative;
-O-, ERICA negative.
tissue/lung metastasis (n = 14), bone and soft tissue/lung
metastasis (n = 5) and visceral metastasis (n = 15). Eight-
seven patients were treated with tamoxifen, 22 patients with
goserelin alone or in combination with tamoxifen and three
patient with megestrol acetate. ER-ICA receptor status cor-
related significantly with UICC assessed response at 6
months, as shown in Table IT. ER-ICA status also correlated
significantly with time to progression of disease (Wilcoxon
statistic = 33.3, 1 d.f.; P<0.0001), (Figure 2) and with sur-
vival (Wilcoxon statistic = 31.0, 1 d.f.; P<0.0001), (Figure
3).
ER-EIA and ER-ICA status combined
Ninety-eight patients had both ER-EIA and ER-ICA status
measured. Comparison of combined ER-EIA/ER-ICA status
vs UICC response at 6 months is shown in Table III. Com-
bining ER-ICA and EIA results did not appear to improve
the prediction of response to endocrine therapy vs either
ER-EIA or ER-ICA status alone (Table III).
Both assays were assessed for sensitivity in predicting res-
ponse (CR + PR) and specificitiy in predicting non-response
(SD + PD): the results were 28/33 (85%) and 60/145 (41%)
respectively for ER-EIA and 29/29 (100%) and 41/83 (49%)
for ERICA. The assays were further evaluated for sensitivity
in predicting non-progression (CR + PR + SD) and specific-
ity for progression (PD): the results for ER-EIA were 67/82
(82%) and 50/96 (52%) respectively and for ERICA 52/58
(90%) and 35/54 (65%). In both analyses, sensitivity and
specificity appeared better by ERICA than ER-EIA.
Discussion
Results obtained from hormone receptor assays must be both
specific (able to predict failure) and sensitive (able to predict
response) in order to provide useful prognostic information.
It has previously been reported that using the ligand binding
assay 32% of patients with ER positive primary tumours
responded (CR + PR/total) to systemic endocrine therapy for
recurrent carcinoma compared to 10% of patients with ER
negative tumours (Williams et al., 1987). Similar response
rates of 25% and 8% in patients with ER positive and
negative tumours respectively, as measured by the ER-EIA
assay, are reported in this paper. Patients with ER-ICA
positive or negative tumours showed 41% or 0% response
rates respectively. Similar response rates for ER-ICA positive
and negative tumours (39% and 0% respectively) have been
reported (McClelland et al., 1986). This present study sup-
ports these results and suggests that the sensitivity and
specificity of the ER-ICA assay for predicting response/non-
respnse or progression/non-progression is better than the
ER-EIA assay.
This study found that ER expression in primary tumours
was significantly higher in the postmenopausal group of
patients. The expression of ER correlated with the age of
patients at initial presentation with breast cancer. The higher
concentrations of ER with increasing age was also seen
between the two postmenopausal age groups (i.e. 50-65 and
>65 years). These latter results suggest that the correlation
of menopausal status with ER expression may simply be a
reflection of the relationship between ER expression and
patient age. High levels of ER expression in the primary
tumours of elderly patients has previously been reported
(Allan et al., 1985; Legha et al., 1978).
Survival from commencing endocrine therapy has pre-
viously been reported to correlate significantly with ER
status by the ligand binding assay (Williams et al., 1986).
Survival from commencing endocrine therapy by ER status
of the primary tumour was significantly longer from patients
with ER positive tumours measured both by ER-EIA and
ER-ICA (Figure 3). The difference in survival between ER
positive and ER negative patients was equally well shown by
ER-ICA and ER-EIA.
Walker and colleagues have previously reported a good
correlation between ER status of the primary tumour as
measured by ER-EIA and ER-ICA (Walker et al., 1988).
This correlation between these two ER assays was confirmed
in this study in that there was agreement on the ER status in
84/98 (85%) of patients (Table ITT). Coombes and colleagues
have reported that ER status measured by ER-ICA is a good
predictor of response to therapy (Coombes et al., 1987). This
Inr- I730 J.F.R. ROBERTSON et al.
paper comparing the value of ER-ICA and ER-EIA assays in
patients with advanced breast cancer extends the observa-
tions regarding ER-ICA by suggesting it is as good a predic-
tor of survival as ER-EIA which requires solubilisation of a
larger portion of tumour tissue. In addition ER-ICA status
has higher sensitivity and specificity than ER-EIA status in
predicting both therapeutic response and progression of
disease on primary endocrine therapy.
The ER-ICA assay has several other distinct advantages.
Firstly ER-ICA can be performed on a small tumour biopsy
sample or even an aspirate (Coombes et al., 1987). Secondly
it provides information on the number of tumour cells ex-
pressing ER and between tumour tissue and its benign com-
ponents. Since a previous study from our group reported that
response rates improved with increasing concentration of ER
estimated by the ligand binding method (Campbell et al.,
1981) the heterogeneity of ER expression by tumour cells
noted on ER-ICA examination is currently the subject of
further research to try and establish the predictive value, if
any, of the % of tumour cells which stain positive both in
primary operable breast cancer and in advanced breast
cancer.
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